A new article has been published advocating the use of chimeric antigen receptor T (CAR T) therapy for the treatment of haematological malignancies in patients with HIV.
Patients with HIV are at an increased risk of cancer, but may not have the same opportunities to receive innovative treatments as other cancer patients. These patients are also often excluded from clinical trials, so their is little evidence to support the use of innovative drugs in this population.
However, post-approval evaluation of anti-CD19 CAR T-cell therapy in people with HIV and aggressive B-cell lymphoma has demonstrated the feasibility of CAR T-cell therapy for cancer. The article showcases the evidence for the safety and efficacy of immunotherapies like CAR-T therapy in patients with HIV and cancer, and highlights the ability of certain immunotherapies to reduce the latent HIV reservoir.